About this trial
The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.
The main purposes of this study are:
1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China; 2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old.
Meets the clinical diagnostic criteria for HAP in the 2018 HAP/VAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature>38 ℃; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count >10 × 10^9/L or <4 × 10^9/L.
Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count >25/low magnification field, epithelial cell count <10/low magnification field, or a ratio of the two >2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture.
obtained informed consent
Disqualifiers
Those who cannot understand and execute the investigation plan.
Active pulmonary tuberculosis;
Severely immunosuppressed patients: absolute neutrophil count <0.5× 10^9/L, CD4<200/ml.
Trial population
hospital-acquired pneumonia adult patients with qualified evidence of responsible pathogen in China
Trial design
Cohort
Prospective
Treatments tested in this trial
prognosis status
Other interventionobservatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
Treatment groups
Trial outcomes
Primary outcomes
mortality at day 28
prognosis
Secondary outcomes
clinical characteristics
symptoms, physical examinations, comorbidity, laboratory tests, imaging findings and treatment
pathogen
molecular characteristics of responsible pathogen; antibiotic resistance of bacteria
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: